Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galapagos NV stock logo
GLPG
Galapagos
$32.71
-0.3%
$29.55
$22.36
$33.86
N/A0.1383,278 shs261,928 shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$24.27
-0.3%
$22.07
$13.45
$41.08
$2.13B0.09982,643 shs860,814 shs
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$4.04
+8.0%
$2.82
$1.11
$5.18
$503.02M2.332.39 million shs4.71 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$33.68
+0.3%
$34.67
$27.12
$55.33
$2.02B2.37891,336 shs1.38 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galapagos NV stock logo
GLPG
Galapagos
0.00%+0.18%+13.44%+19.64%+22.65%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
0.00%-0.94%+9.87%+15.96%-43.62%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
0.00%-4.04%+27.85%+140.48%-27.99%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.00%-6.42%-11.62%-14.17%-39.65%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Galapagos NV stock logo
GLPG
Galapagos
0.3569 of 5 stars
0.72.00.00.02.60.00.6
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
4.1737 of 5 stars
4.41.00.04.43.21.70.0
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
3.8678 of 5 stars
4.41.00.00.03.75.00.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.5548 of 5 stars
3.40.00.04.43.30.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Galapagos NV stock logo
GLPG
Galapagos
1.43
Strong Sell$25.33-22.55% Downside
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.77
Moderate Buy$48.0998.15% Upside
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
2.75
Moderate Buy$9.25128.96% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4049.64% Upside

Current Analyst Ratings Breakdown

Latest PRME, IDYA, TWST, and GLPG Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/28/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$66.00 ➝ $72.00
7/22/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
7/16/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$8.00
7/10/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold$25.00
7/9/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$57.00 ➝ $30.00
6/26/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$44.00
6/26/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$44.00
5/27/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$10.00 ➝ $1.50
5/22/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.00
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.00
5/20/2025
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Galapagos NV stock logo
GLPG
Galapagos
$298.31MN/A$0.73 per share45.05$47.57 per shareN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$7M303.65N/AN/A$12.25 per share1.98
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$3.85M141.28N/AN/A$1.37 per share2.95
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$312.97M6.45N/AN/A$8.07 per share4.17
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Galapagos NV stock logo
GLPG
Galapagos
$80.16MN/A0.00N/AN/AN/AN/AN/A10/22/2025 (Estimated)
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/4/2025 (Confirmed)

Latest PRME, IDYA, TWST, and GLPG Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.85N/AN/AN/A$3.48 millionN/A
8/4/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
5/6/2025Q1 2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Galapagos NV stock logo
GLPG
Galapagos
N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
$1.4535.79%N/AN/A N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Galapagos NV stock logo
GLPG
Galapagos
N/A
8.08
7.99
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
13.92
13.92
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
N/A
6.50
6.50
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
Galapagos NV stock logo
GLPG
Galapagos
32.46%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
98.29%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
70.37%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Galapagos NV stock logo
GLPG
Galapagos
2.91%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.50%
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
22.93%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Galapagos NV stock logo
GLPG
Galapagos
1,310N/AN/AOptionable
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8087.58 million85.39 millionOptionable
Prime Medicine, Inc. stock logo
PRME
Prime Medicine
234134.50 million100.38 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

Preview: Twist Bioscience's Earnings
Twist Bioscience: Still Not There Yet

New MarketBeat Followers Over Time

Media Sentiment Over Time

Galapagos stock logo

Galapagos NASDAQ:GLPG

$32.71 -0.11 (-0.34%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$32.66 -0.05 (-0.14%)
As of 08/1/2025 07:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$24.27 -0.08 (-0.33%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$24.28 +0.01 (+0.04%)
As of 08/1/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Prime Medicine stock logo

Prime Medicine NYSE:PRME

$4.04 +0.30 (+8.02%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$4.34 +0.30 (+7.33%)
As of 08/1/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$33.68 +0.11 (+0.33%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$33.98 +0.30 (+0.89%)
As of 08/1/2025 06:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.